Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.00%
)
US TECH 100
24,089.60
(
-0.18%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
103.82
(
3.15%
)
Bitcoin
72,357.28
(
-2.14%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 180694

Thursday, 12/11/2014 10:49:59 AM

Thursday, December 11, 2014 10:49:59 AM

Post# of 257253
FDA advisory panel for NVS’ Neupogen FoB scheduled for 1/7/15:

http://www.mmm-online.com/fda-plans-review-of-sandozs-neupogen-biosimilar/article/387688/

This will be the FDA’s first-ever advisory panel for a submission under the 351(k) regulatory pathway.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now